• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Phio Pharmaceuticals Announces New Chief Financial Officer

    8/1/24 8:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email

    Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for accounting, finance, treasury, investor relations and administration.

    Mr. Infarinato comes to Phio with more than 20 years of financial and accounting leadership experience. He most recently was head of a consulting firm, advising on operational matters including the funding and IPO process. Previous positions include serving as Chairman of the Board of Trustees and Chair of the Finance Committee with Abington Health, executive Vice President and CFO of an international service company, Vice President Taxation and Corporate Controller at Rhone Poulenc Rorer, and Treasurer and Tax Manager-Europe for Pfizer.

    "I am pleased to welcome Robert to the Phio executive management team," said Robert Bitterman, CEO of Phio Pharmaceuticals. "Bob's skillset is only exceeded by his breadth of experience across multiple financial functions within the health care space. I look forward to his participation as a valuable contributor in guiding our company forward."

    About Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

    For additional information, visit the Company's website, www.phiopharma.com.

    Contact:
    Phio Pharmaceuticals Corp.
    [email protected]

    PR Contact
    Michael Adams
    Bridge View Media
    [email protected]

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218434

    Get the next $PHIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Carson Lisa Cabott

      3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/18/25 4:30:56 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 5:00:01 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 4:59:45 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    SEC Filings

    See more
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      7/25/25 1:36:29 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      7/7/25 4:01:40 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      6/25/25 8:46:08 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

      6/5/25 7:35:43 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      6/14/21 6:22:20 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 5:00:01 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 4:59:45 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/10/25 4:43:57 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

      King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of

      7/25/25 3:04:00 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

      Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that pathologic results are available for four of the five patients treated in the fourth cohort. A complete pathologic response (100% tumor clearance) has been reported for one patient with cutaneous squamous cell carcinoma (cSCC). One patient with metastatic Merkel cell carc

      7/25/25 12:36:00 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

      Agreement covers contract development and manufacturing of lead compound PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today it has entered into a comprehensive drug substance development services agreement with a U.S. manufacturer. The company will provide analytical and process development and cGMP manufacture of Phio's lead clinical development compound PH-762. This represents a critical next step in advancing Phio's intratumoral program to treat cutaneous

      7/25/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

      6/24/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

      5/1/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

      Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

      2/20/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      11/13/24 11:20:45 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/6/24 10:30:10 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/8/23 6:07:04 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care